A study to evaluate the effect of metformin, oral contraceptive pills and their combination on anthropometric measurements, lipid profile and hs-CRP levels in Indian women with polycystic ovary syndrome at a tertiary care hospital
Year: 2024
Type: article
Abstract: Objectives: The study evaluated effect of metformin, oral contraceptive pills (OCP), and their combination on highsensitivity C-reactive protein (hs-CRP), lipid profile, and anthropometric measurements (body mass index, waist circumference, hip circumference, waist -hip ratio) in Indian women with PCOS (polycystic ovary syndrome).Methods: In this prospective, observational, open-label study, metformin, OCP, and their combination were compared in women with PCOS (Rotterdam criteria).Lipid parameters, hs-CRP, anthropometric measurements, menstrual cycle, and Ferriman -Gallway (FG) score were evaluated at baseline, three and six months after treatment.Results: A total of 88 patients completed study.hs -CRP levels significantly decreased in metformin and combination groups (p <0.001) at 3 and 6 months, while they increased in OCP group (p<0.001).Anthropometric measurements significantly decreased in metformin (p<0.001) and combination groups (p<0.05),whereas an increase in these variables was observed in OCP group (p<0.05).Administration of metformin (p<0.001) and combination (p<0.05)resulted in improvement in lipid profile, whereas treatment with OCP (p<0.05) has led to unfavorable lipid profile.FG score and menstrual irregularity improved in all groups.Conclusion: Metformin may be a better treatment option for OCPs in ameliorating atherogenic profile in Indian women with PCOS.For patients requiring OCP, combination of metformin with OCP can be preferred to OCP alone as metformin has been shown to reduce cardiovascular risk induced by OCP.Combination of metformin and OCP has regularized menstrual cycle better than monotherapy of either drug.Keywords: Inflammatory marker, dyslipidemia, body mass index, polycystic ovary syndrome, combined oral contraceptives and metformin.Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women, with an estimated prevalence of 2.2-26 % 1 .PCOS can be diagnosed if two of following three criteria is met (Rotterdam criteria): hyperandrogenism, ovulatory dysfunction, or polycystic ovaries.They can manifest as symptoms of menstrual irregularities, acne, or hirsutism 2 .PCOS is associated with group of metabolic derangements, including obesity, dyslipidemia, hypertension, subclinical inflammation, and insulin resistance (IR).IR plays crucial role in pathogenesis and progression of PCOS.IR has been seen in approximately 70% of obese and 30-50% of lean PCOS women, independent of obesity.IR and
Source: The New Indian Journal of OBGYN
Institution: Nizam's Institute of Medical Sciences
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4406619642